These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31547735)

  • 1. Clinical significance of plasma free DNA in patients with non-small cell lung cancer.
    Ma L; Du J; Sui Y; Wang S
    J Int Med Res; 2019 Nov; 47(11):5593-5600. PubMed ID: 31547735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer.
    van der Drift MA; Hol BE; Klaassen CH; Prinsen CF; van Aarssen YA; Donders R; van der Stappen JW; Dekhuijzen PN; van der Heijden HF; Thunnissen FB
    Lung Cancer; 2010 May; 68(2):283-7. PubMed ID: 19632736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.
    Paci M; Maramotti S; Bellesia E; Formisano D; Albertazzi L; Ricchetti T; Ferrari G; Annessi V; Lasagni D; Carbonelli C; De Franco S; Brini M; Sgarbi G; Lodi R
    Lung Cancer; 2009 Apr; 64(1):92-7. PubMed ID: 18804892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a new generation of capillary electrophoresis to quantify circulating free DNA in non-small cell lung cancer.
    Chiappetta C; Anile M; Leopizzi M; Venuta F; Della Rocca C
    Clin Chim Acta; 2013 Oct; 425():93-6. PubMed ID: 23892142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
    Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
    J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease.
    Szpechcinski A; Chorostowska-Wynimko J; Struniawski R; Kupis W; Rudzinski P; Langfort R; Puscinska E; Bielen P; Sliwinski P; Orlowski T
    Br J Cancer; 2015 Jul; 113(3):476-83. PubMed ID: 26125447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of serum MET in non-small-cell lung cancer and its clinical significance.
    Li D; Li F; Wu Y; Zhou D; Chen H
    Clin Biochem; 2015 Feb; 48(3):110-4. PubMed ID: 25489726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of free-circulating DNA in plasma of patients with resectable NSCLC.
    Szpechcinski A; Chorostowska-Wynimko J; Kupis W; Maszkowska-Kopij K; Dancewicz M; Kowalewski J; Orlowski T
    Expert Opin Biol Ther; 2012 Jun; 12 Suppl 1():S3-9. PubMed ID: 22559166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of free circulating DNA as a diagnostic marker in lung cancer.
    Sozzi G; Conte D; Leon M; Ciricione R; Roz L; Ratcliffe C; Roz E; Cirenei N; Bellomi M; Pelosi G; Pierotti MA; Pastorino U
    J Clin Oncol; 2003 Nov; 21(21):3902-8. PubMed ID: 14507943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum tumour markers and management of non-small cell lung cancer.
    Splinter TA
    Lung Cancer; 1995 Oct; 13(2):177-9. PubMed ID: 8581397
    [No Abstract]   [Full Text] [Related]  

  • 11. Letter to the Editor: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy".
    Nicolazzo C; Raimondi C; Loreni F; Gazzaniga P; Gradilone A
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Assay of methylated gene RARbeta2 in circulating DNA of blood from patients with lung cancer as a potential prognostic marker].
    Ponomareva AA; Rykova EIu; Cherdyntseva NV; Skvortsova TE; Dobrodeev AIu; Litviakov NV; Zav'ialov AA; Tuzikov SA; Vlasov VV; Laktionov PP
    Vopr Onkol; 2011; 57(3):302-7. PubMed ID: 21882599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating endothelial progenitor cells are increased in human lung cancer and correlate with stage of disease.
    Nowak K; Rafat N; Belle S; Weiss C; Hanusch C; Hohenberger P; Beck GCh
    Eur J Cardiothorac Surg; 2010 Apr; 37(4):758-63. PubMed ID: 19896859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy.
    Kumar S; Guleria R; Singh V; Bharti AC; Mohan A; Das BC
    Lung Cancer; 2010 Nov; 70(2):211-7. PubMed ID: 20181407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.
    Powrózek T; Krawczyk P; Nicoś M; Kuźnar-Kamińska B; Batura-Gabryel H; Milanowski J
    Clin Transl Oncol; 2016 Apr; 18(4):398-404. PubMed ID: 26311076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reply to the Letter to the Editor by C. Nicolazzo et al.: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy".
    Alama A; Coco S; Vanni I; Grossi F
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating microRNAs: possible prediction biomarkers for personalized therapy of non-small-cell lung carcinoma.
    Gao W; Liu L; Lu X; Shu Y
    Clin Lung Cancer; 2011 Jan; 12(1):14-7. PubMed ID: 21273174
    [No Abstract]   [Full Text] [Related]  

  • 18. Plasma exosome levels in non-small-cell lung cancer: Correlation with clinicopathological features and prognostic implications.
    Liu Q; Xiang Y; Yuan S; Xie W; Li C; Hu Z; Wu N; Wu L; Yu Z; Bai L; Li Y
    Cancer Biomark; 2018; 22(2):267-274. PubMed ID: 29660899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic abnormalities in plasma DNA of patients with lung cancer and other respiratory diseases.
    Khan S; Coulson JM; Woll PJ
    Int J Cancer; 2004 Jul; 110(6):891-5. PubMed ID: 15170672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer.
    Kumar S; Guleria R; Singh V; Bharti AC; Mohan A; Das BC
    Eur Respir J; 2010 Oct; 36(4):885-92. PubMed ID: 20185420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.